This becomes even more concerning in RA and inflammatory bowel disease (IBD) patients who are on anti-TNF-α therapy despite the fact that it is not clear how anti- TNF-α therapy may dysregulate ACE2 expression and shedding. Here, TNF is linked to inflammatory bowel disease.